Germany
· Delayed Price · Currency is EUR BioNxt Solutions Company Description
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland.
The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide.
It also offers diagnostic screening tests; new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications.
The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022.
BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2017 |
| Industry | Pharmaceutical Preparations |
| CEO | Wolfgang Probst |
Contact Details
Address: 1928 Linden Road Vancouver, British Columbia V6M 1E7 Canada | |
| Phone | 780 818 6422 |
| Website | bionxt.com |
Stock Details
| Ticker Symbol | BXT |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Wolfgang Probst | Chief Executive Officer |